Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
Under specific conditions, TARE can be a more cost-effective treatment than DEB-TACE. If the reimbursement price of radioactive microspheres is set approximately 2.8% lower than that in the United Kingdom, TARE could be cost-effective compared with DEB-TACE.
Authors
- So Sato (ORCID: https://orcid.org/0000-0003-1265-6835)
- Shotaro Aso (ORCID: https://orcid.org/0000-0002-7804-2433)
- Go Shirota (ORCID: https://orcid.org/0000-0003-4215-3710)
- Daisuke Itoh
- Osamu Abe
- Masaaki Akahane
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
Institutions
- University of Tokyo Health Sciences (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Japanese Journal of Radiology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1007/s11604-024-01640-1
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- Ministry of Health, Labour and Welfare
- University of Tokyo
- Japan Society for the Promotion of Science